exRNAdisease

General Information

Database ID:

exR0089249

RNA Name:

hsa-miR-625-5p

RNA Type:

miRNA

Chromosome:

chr14

Starnd:

Coordinate:

Start Site(bp):

65471116

End Site(bp):

65471136

External Links:

Disease Information

Disease Name:	Breast Cancer
Disease Category:	Cancers
MeSH ID:	D001943
Type:	Neoplasms/Breast Neoplasms
Alias:	Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID:	GSE101841
Description:	Serum microRNA profile of Her2 positive metastatic breast cancer patients
Experimental Design:	Trastuzumab therapy
Case Disease Type:	Breast Cancer
Case Disease SubType:	HER2 positive metastatic breast cancer
Case Sample:	Breast Cancer Trastuzumab resistant
Control Sample:	Trastuzumab sensitive
Number of Case:	42
Number of Control:	61
Number of Samples:	103

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
PPP2R1A	chr19	52190048	52229518	+
SF3B3	chr16	70523791	70577670	+
LRFN1	chr19	39306568	39315336	-
SLC6A6	chr3	14402576	14489349	+
VPS37B	chr12	122865330	122896127	-
SMARCC2	chr12	56162359	56189567	-
WIZ	chr19	15419978	15449956	-
SLC7A5	chr16	87830023	87869507	-
MED22	chr9	133338312	133348131	-
PPARD	chr6	35342558	35428191	+
FAM102A	chr9	127940582	127980989	-
ABL2	chr1	179099330	179229684	-
PPP6C	chr9	125146573	125189939	-
ABCF2	chr7	151207837	151227166	-
ABHD14A-ACY1	chr3	51974706	51989183	+
BCL9L	chr11	118893875	118925608	-
JUN	chr1	58780791	58784047	-
NUMB	chr14	73275107	73458617	-
SDF2	chr17	28648346	28662189	-
SREBF2	chr22	41833079	41907307	+
COL6A2	chr21	46098112	46132848	+
ACY1	chr3	51983340	51989197	+
E2F1	chr20	33675477	33686385	-
PRDX2	chr19	12796820	12801800	-
MSI1	chr12	120341330	120369164	-
COPS7B	chr2	231781671	231809254	+
CPSF7	chr11	61402641	61430031	-
SCAMP4	chr19	1905372	1926013	+
ITGA5	chr12	54395261	54419266	-
RNF44	chr5	176526712	176538025	-

miRNA targets:

circRNA targets:

circRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
hsa_circ_0001434	chr4	106345352	106377902	-
hsa_circ_0001409	chr4	48835417	48859382	+
hsa_circ_0001358	chr3	169694733	169706147	+
hsa_circ_0001146	chr20	34241449	34246936	-

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC010542.4	chr16	66549280	66551189	+
AC145207.5	chr17	81878425	81881106	-
AC234582.1	chr1	155195004	155205495	+
H19	chr11	1995176	2001470	-
LINC00240	chr6	26956932	27059749	+
MALAT1	chr11	65497688	65506516	+
SNHG7	chr9	136721366	136728184	-
XIST	chrX	73820649	73852723	-

Display:

Experiment Detail

GEO ID:	GSE101841
Sample Source:	Blood
Source Fraction:	Serum
Platform:	GPL23138
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	1808
Sample treatment protocol:	NA
RNA Extract protocol:	Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions.
RNA library preparation protocol:	Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID:	29691399
Title:	A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.
Author:	Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E
Journal:	Nat Commun. 2018 Apr 24;9(1):1614.
Description:	MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.